替诺福韦艾拉酚胺与替诺福韦二吡呋酯预防慢性乙型肝炎母亲垂直传播的比较:系统综述与Meta分析
该系统综述与Meta分析纳入31项研究,比较了高病毒载量慢性乙型肝炎母亲接受替诺福韦二吡呋酯(TDF)、替诺福韦艾拉酚胺(TAF)或不治疗对母婴传播的预防效果与安全性。结果显示TDF较对照组显著降低6-12月龄婴儿母婴传播率(风险比0.10,95%CI 0.07-0.16),TAF与TDF在降低母婴传播上效果相似,所有方案对母婴均无安全性担忧。
要点
- TDF较不治疗显著降低6-12月龄婴儿母婴传播率(风险比0.10,95%CI 0.07-0.16)。
- TAF与TDF降低母婴传播效果相似(配对Meta分析风险比1.09,95%CI 0.16-7.61)。
- 所有方案对母亲和婴儿均无安全性担忧。
核心结论
- 与安慰剂或不治疗相比,母亲接受TDF和TAF预防在高病毒载量母亲中降低母婴传播同样有效且无安全性担忧。
研究设计与样本
- 系统综述与Meta分析,检索多个数据库从建库至2024年3月31日,纳入队列研究和随机对照试验,共31项研究,包括2588名接受TDF的高病毒载量母亲、280名接受TAF的母亲和1600名不接受治疗的母亲。
主要发现
- 与对照组相比,TDF治疗降低6-12月龄婴儿的母婴传播率(风险比0.10,95%CI 0.07-0.16)。
- TAF与TDF配对Meta分析显示降低母婴传播效果相似(风险比1.09,95%CI 0.16-7.61)。
- 网络Meta分析显示两种方案降低母婴传播效力相等(风险比1.09,95%CI 0.15-7.65)。
- 累积排名曲线下面积显示TDF为最佳方案(概率排名0.77 vs TAF 0.72),妊娠期接受安慰剂效力最低(概率排名0.01)。
- 所有方案对母亲和婴儿均无安全性担忧。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: International guidelines recommend maternal tenofovir disoproxil fumarate (TDF) therapy accompanied by infant immunoprophylaxis to prevent hepatitis B virus (HBV) mother-to-child transmission (MTCT) in highly viremic mothers. However, pooled analyses for tenofovir alafenamide (TAF) effects and comparisons between the 2 regimens are lacking. DESIGN: In this meta-analysis, pairs of independent reviewers performed multiple database searches from inception to 31 March 2024 and extracted data from cohort studies and randomized controlled trials (RCTs) in highly viremic mothers. The outcomes of interest were the reduction of MTCT and safety in the TDF-treated, TAF-treated, and control groups. RESULTS: We included 31 studies with 2588 highly viremic mothers receiving TDF, 280 receiving TAF, and 1600 receiving no treatment. Compared to the control, TDF therapy reduced the MTCT rate in infants aged 6-12 months (risk ratio: 0.10, 95% confidence interval [CI] .07-.16). Pairwise meta-analysis between TAF and TDF revealed similar effects on reducing MTCT (risk ratio: 1.09, 95% confidence interval .16-7.61). Network meta-analysis showed equal efficacy of the 2 regimens in reducing MTCT (risk ratio: 1.09, 95% CI .15-7.65). The surface under the cumulative ranking curve revealed TDF as the best regimen compared with TAF (probability ranking: .77 vs .72), while receiving a placebo during pregnancy had the lowest efficacy (probability ranking 0.01). There were no safety concerns for mothers and infants in all regimens. CONCLUSIONS: Compared to placebo or no treatment, maternal TDF and TAF prophylaxis are equally effective and without safety concerns in reducing MTCT in highly viremic mothers.
引用
- Pan CQ, Zhu L, Yu AS, et al. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Preventing Vertical Transmission in Chronic Hepatitis B Mothers: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2024. PMID: 38805690. doi:10.1093/cid/ciae288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。